BEBT-908 for injection

DRUG3 trials

Sponsors

BeBetter Med Inc

Conditions

Relapsed or Refractory Diffuse Large B-cell LymphomaRelapsed or Refractory Multiple MyelomaRelapsed or Refractory Non-Hodgkin's LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

CompletedNCT06082596

BeBetter Med IncRelapsed or Refractory Multiple Myeloma, Relapsed or Refractory Non-Hodgkin's Lymphoma

Start: 2016-03-02End: 2019-03-08Updated: 2023-10-13

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2023-12-01End: 2025-11-05Target: 75Updated: 2023-12-11

Phase 2

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

BeBetter Med IncRelapsed or Refractory Diffuse Large B-cell Lymphoma

Start: 2020-06-12End: 2023-12-25Target: 128Updated: 2023-10-11

Related Papers

Efficacy and safety of ifupinostat (BEBT-908) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma: Results from an exploratory phase Ib study.

Journal of Clinical Oncology2025-05-281 citations